Transenterix Inc (NYSEAMERICAN:TRXC) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 14,893,810 shares, an increase of 7.4% from the November 15th total of 13,862,996 shares. Currently, 10.2% of the company’s stock are short sold. Based on an average daily volume of 3,705,307 shares, the short-interest ratio is presently 4.0 days.

Transenterix (TRXC) traded down $0.06 during trading on Monday, hitting $2.17. 1,987,060 shares of the stock were exchanged, compared to its average volume of 3,225,756. Transenterix has a one year low of $0.45 and a one year high of $5.00.

In related news, insider Todd Pope sold 600,000 shares of the company’s stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $3.68, for a total value of $2,208,000.00. Following the completion of the transaction, the insider now directly owns 462,644 shares of the company’s stock, valued at approximately $1,702,529.92. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Joseph P. Slattery sold 529,609 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $2.80, for a total transaction of $1,482,905.20. Following the completion of the transaction, the chief financial officer now directly owns 440,974 shares of the company’s stock, valued at $1,234,727.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,462,609 shares of company stock valued at $4,666,595.

A hedge fund recently raised its stake in Transenterix stock. Ladenburg Thalmann Financial Services Inc. increased its position in Transenterix Inc (NYSEAMERICAN:TRXC) by 87.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 79,150 shares of the medical instruments supplier’s stock after purchasing an additional 37,000 shares during the quarter. Ladenburg Thalmann Financial Services Inc. owned approximately 0.05% of Transenterix worth $113,000 as of its most recent SEC filing.

A number of research firms have recently commented on TRXC. Ladenburg Thalmann Financial Services set a $5.00 price objective on shares of Transenterix and gave the stock a “buy” rating in a research note on Friday, October 20th. Stifel Nicolaus increased their price objective on shares of Transenterix from $3.75 to $4.00 and gave the stock a “buy” rating in a research note on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. Transenterix currently has an average rating of “Hold” and a consensus target price of $2.61.

ILLEGAL ACTIVITY WARNING: “Transenterix Inc (TRXC) Short Interest Up 7.4% in November” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/11/transenterix-inc-trxc-short-interest-up-7-4-in-november.html.

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.